CONFIRMED: Johnson & Johnson is looking to buy a nearly $20 billion drugmaker

Johnson & Johnson is looking to buy the Swiss drugmaker Actelion in what could be a nearly $20 billion deal.

Actelion on Friday confirmed J&J’s interest, after Bloomberg first reported the potential takeover Thursday.

Shares of Actelion have jumped 16.7% to 184.40 Swiss francs ($182) since Thursday morning, giving the company a market cap of around 19.4 billion Swiss francs ($19.15 billion).

The two companies are in early talks, Bloomberg reported, and a deal may not necessarily materialise.

NOW WATCH: Richard Branson: Entrepreneurs need to fill the gap where government is lacking

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at